{Reference Type}: Editorial
{Title}: Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy.
{Author}: Scafuri L;Buonerba C;Di Lauro V;Tortora V;Cascella M;Liguori L;Sciarra A;Sabbatino F;Diana A;Marra A;Tarantino P;Trapani D;Giuliano M;Arpino G;Curigliano G;Di Lorenzo G;
{Journal}: Oncol Ther
{Volume}: 12
{Issue}: 3
{Year}: 2024 Sep 28
暂无{DOI}: 10.1007/s40487-024-00286-3
{Abstract}: <B>BACKGROUND: </B>Breast cancer presents diverse molecular subtypes affecting treatment strategies. Human epidermal growth factor receptor 2 (HER2)-low, hormone receptor-positive (HR+) breast cancer poses a challenge due to limited targeted therapies. Current neoadjuvant treatment primarily utilizes chemotherapy, with conflicting results regarding efficacy in patients with HER2-low breast cancer. Trastuzumab deruxtecan (T-DXd) shows promise in HER2-low metastatic disease, and preliminary evidence suggests synergy with endocrine therapy.<BR><B>OBJECTIVE: </B>This editorial explores the hypothesis that neoadjuvant T-DXd with or without endocrine therapy offers efficacy in the clinical management of HR+/HER2-low breast cancer.<BR><B>METHODS: </B>We propose a phase II study with two treatment arms: T-DXd + letrozole and T-DXd alone. The primary endpoint is the radiological complete response rate. Secondary endpoints include pathological complete response rate, safety, event-free survival, and overall survival. Exploratory analyses will compare the arms to identify potential for optimizing treatment efficacy and minimizing side effects.<BR><B>CONCLUSIONS: </B>This study design allows for initial assessment of T-DXd with or without endocrine therapy in the treatment of HER2-low breast cancer. The findings may pave the way for personalized treatment strategies and inform future research, potentially leading to a chemotherapy-sparing approach.